Kocabora S M, Fazil K, Ozsutcu M, Doyduk-Kocabora A, Gulkilik G
Bull Soc Belge Ophtalmol. 2013(322):7-12.
To assess the efficacy of subconjunctival bevacizumab injection as adjuvant therapy in the prevention of recurrence following the surgical treatment of pterygium by comparison with intraoperative mitomycin-C application.
This prospective comparative study included thirty consecutive patients with primary nasal pterygium that were surgically treated with simple excision. In addition to surgical excision, subconjunctival bevacizumab was injected in 15 eyes (group A), and, in the remaining 15 eyes, topical mitomycin-C 0.2 mg/mL was applied for 2 minutes (group B). The postoperative outcome was followed clinically for a minimum of 12 months. The main outcome criteria were recurrence rate and postoperative complications.
A significantly higher recurrence rate was found in bevacizumab group (66.7%) compared to MMC group (26.7%) (P= 0.028). In group A, conjunctival wound separation was observed in 3 of 15 eyes; however, no conjunctival separation was observed in Group B and no other serious complications were observed in either group.
The intraoperative use of subconjunctival bevacizumab does not seem to be effective in reducing the rate of pterygium recurrence following excision when compared with intraoperative mitomycin-C application.
通过与术中应用丝裂霉素C对比，评估结膜下注射贝伐单抗作为辅助治疗在预防翼状胬肉手术治疗后复发中的疗效。
这项前瞻性对照研究纳入了30例连续的原发性鼻侧翼状胬肉患者，均接受单纯切除术。除手术切除外，15只眼结膜下注射贝伐单抗（A组），其余15只眼局部应用0.2mg/mL丝裂霉素C 2分钟（B组）。术后临床随访至少12个月。主要观察指标为复发率和术后并发症。
贝伐单抗组复发率（66.7%）显著高于丝裂霉素C组（26.7%）（P = 0.028）。A组15只眼中有3只观察到结膜伤口裂开；然而，B组未观察到结膜裂开，两组均未观察到其他严重并发症。
与术中应用丝裂霉素C相比，术中结膜下注射贝伐单抗在降低翼状胬肉切除术后复发率方面似乎无效。
